OnKure director granted 15,300 stock options

OnKure Therapeutics director Liam Ratcliffe received a new stock option grant as part of compensation.

Accepted by SEC EDGAR 04/01/2026 - 05:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics director Liam Ratcliffe received a new stock option grant as part of compensation. The award covers 15,300 options to buy Class A common stock at an exercise price of $4.14 per share, expiring on March 30, 2036.

These options vest over time: 1/36 of the grant vests on April 30, 2026 and 1/36 on the last day of each following month, as long as he continues as a service provider. After this grant, he holds 15,300 stock options directly from this award.

Insider Trade Summary

Grant/Award: 15,300 shares

Grant/Award 1 txn

Insider Ratcliffe Liam

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,300	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 15,300 contracts (Direct)

Footnotes (1)

1. F1. 1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Key Figures

Stock options granted: 15,300 options Exercise price: $4.14 per share Expiration date: March 30, 2036 +3 more

6 metrics

Stock options granted 15,300 options Grant to director Liam Ratcliffe on March 31, 2026

Exercise price $4.14 per share Strike price for new options

Expiration date March 30, 2036 Option term end date

Underlying shares 15,300 shares Class A common stock underlying the options

Vesting schedule 1/36 monthly Starts April 30, 2026, then last day of each month

Post-grant derivative holdings 15,300 options Total options held from this award after the transaction

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, vesting

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: "4.1400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

""1/36th of the shares subject to the option shall vest""

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OnKure Therapeutics (OKUR) director Liam Ratcliffe report on this Form 4?

Liam Ratcliffe reported receiving a stock option grant for 15,300 shares of Class A common stock at a $4.14 exercise price. This award is compensation-related, not an open‑market purchase or sale, and increases his derivative-based exposure to OnKure shares.

How many OnKure (OKUR) shares are covered by Liam Ratcliffe’s new option grant?

The new stock option grant covers 15,300 shares of OnKure Therapeutics Class A common stock. These are underlying shares that may be acquired in the future if the options vest and are exercised according to the award’s terms and conditions.

What is the exercise price and expiration for Liam Ratcliffe’s OnKure (OKUR) options?

The options have a $4.14 per share exercise price and expire on March 30, 2036. This means Ratcliffe can buy shares at $4.14, once vested, any time before the March 2036 expiration date, subject to plan and award terms.

How do Liam Ratcliffe’s OnKure (OKUR) options vest over time?

The options vest in monthly installments over three years. One‑thirty‑sixth vests on April 30, 2026, and one‑thirty‑sixth vests on the last day of each subsequent month, contingent on Ratcliffe continuing as a service provider through each applicable vesting date.

Is Liam Ratcliffe’s Form 4 for OnKure (OKUR) a market buy or sell of shares?

No, this Form 4 reflects a grant of stock options as compensation, coded as an acquisition (A). It is not an open‑market purchase or sale of common shares, but a new derivative award that could lead to future share ownership if exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ratcliffe Liam

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	03/31/2026		A		15,300		(1)	03/30/2036	Class A Common Stock	15,300	$0	15,300	D

Explanation of Responses:

1. 1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Rogan Nunn, by power of attorney	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)